Gold is 2025’s best performer. UBS sees more upside
SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS) director Gerhard Prante recently sold 1,150 shares of the company’s Class A common stock. The transaction, which took place on February 14, 2025, was executed at a price of $2.60 per share, amounting to a total sale value of $2,990. The sale comes amid significant stock price volatility, with shares down over 85% in the past year and currently trading near their 52-week low of $2.17.
Following this transaction, Prante retains ownership of 15,757 shares in Cibus. The sale was conducted automatically under a Rule 10b5-1 trading plan, which Prante had established on August 16, 2024. This plan allows for pre-scheduled stock transactions, providing a structured approach to selling shares.
Cibus, Inc., headquartered in San Diego, operates in the agriculture chemicals industry, focusing on innovative solutions in the sector. With a market capitalization of $77.91 million, the company is currently trading below its InvestingPro Fair Value and is scheduled to report earnings on February 28, 2025. Investors can access detailed analysis and 12 additional ProTips through InvestingPro’s comprehensive research report.
In other recent news, Cibus Inc. has been the subject of several significant developments. Canaccord Genuity analysts have adjusted their outlook on Cibus, reducing the stock’s price target from $20.00 to $18.00, while maintaining a Buy rating. This revision follows Cibus’s announcement of a direct stock offering, intending to raise approximately $22.6 million for the advancement of its gene-edited plant productivity traits and further development of its soybean platform.
In another development, Cibus’s Compensation Committee approved a new base salary of $320,000 for executive Carlo Broos, as disclosed in a recent filing with the Securities and Exchange Commission. The details surrounding this adjustment remain undisclosed.
Simultaneously, Jefferies has lowered its price target for Cibus to $5.00, while keeping its Hold rating. The firm’s decision is based on Cibus’s strategic management of its balance sheet and the potential for improved negotiation power if the European Union approves gene editing in the upcoming year. The company’s path to free cash flow breakeven is contingent on successful development of either a soy or wheat trait, or the ability to get its product across 2 to 5 million acres. These are recent developments that investors should take note of.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.